Matinas Biopharma Holdings Inc (MTNB)

[RealFooFighters]

Tuesday’s 2022 update, lot’s of moving parts, some stuff:

1) We want to hear feedback from the FDA meeting (hopefully no delays?), specifically;

A) Will they accept EnACT’s Phase 2 trial as a sufficient (e.g. registrational) to approve?
- Initially for Step-down (based on Cohort 1 & 2)
- Subsequently for Consolidation (based on 1-4)
- Ultimately for Induction (based on Cohort 4)
Or will they require a Phase 3 Trial (larger population/other geographies/US patients?)

B) Guidance on what's the fastest approval track possible (given they have multiple fast-track designations)?
- Matinas wants to know what the shortest point between A & B (regardless of what you call it!)

* Note: They already mentioned they expect a Phase 3 (all-in) trial for other IFI indications!

2) MAT2203 “Go to Market” Strategy/Funding?

3) NIH/UNC in vivo study update?

4) Genentech’s collaborations/next steps?

5) New Partners/Licensing deals (cash)?

6) Treasury Update (RS, Uplisting plans, ..)?

7) Complete 5-year MAT2203 data (Dec scheduled completion)

8) Update of MAT2501 Phase 1 / CFF next round funding?